Drug Development Research,
Journal Year:
2024,
Volume and Issue:
85(2)
Published: April 1, 2024
Abstract
Icaritin
is
a
natural
prenylated
flavonoid
derived
from
the
Chinese
herb
Epimedium.
The
compound
has
shown
antitumor
effects
in
various
cancers,
especially
hepatocellular
carcinoma
(HCC).
exerts
its
anticancer
activity
by
modulating
multiple
signaling
pathways,
such
as
IL‐6/JAK/STAT3,
ER‐α36,
and
NF‐κB,
affecting
tumor
microenvironment
immune
system.
Several
clinical
trials
have
evaluated
safety
efficacy
of
icaritin
advanced
HCC
patients
with
poor
prognoses,
who
are
unsuitable
for
conventional
therapies.
results
demonstrated
that
can
improve
survival,
delay
progression,
produce
benefits
these
patients,
favorable
profile
minimal
adverse
events.
Moreover,
enhance
response
regulating
function
phenotype
cells,
CD8+
T
MDSCs,
neutrophils,
macrophages.
These
findings
suggest
promising
candidate
immunotherapy
other
cancers.
However,
further
studies
needed
to
elucidate
molecular
mechanisms
optimal
dosing
regimens
potential
synergistic
agents.
Therefore,
this
comprehensive
review
scientific
literature
aims
summarize
advances
knowledge
preclinical
well
pharmacokinetic,
metabolism,
toxicity,
action
recognize
main
challenge,
gaps,
opportunities
develop
medication
cancer
use.
Thus,
our
objective
was
clarify
current
state
use
an
drug.
Cells,
Journal Year:
2022,
Volume and Issue:
11(14), P. 2209 - 2209
Published: July 15, 2022
Natural
products
play
a
critical
role
in
the
discovery
and
development
of
numerous
drugs
for
treatment
various
types
cancer.
These
phytochemicals
have
demonstrated
anti-carcinogenic
properties
by
interfering
with
initiation,
development,
progression
cancer
through
altering
mechanisms
such
as
cellular
proliferation,
differentiation,
apoptosis,
angiogenesis,
metastasis.
Treating
multifactorial
diseases,
agents
targeting
single
target,
might
lead
to
limited
success
and,
many
cases,
unsatisfactory
outcomes.
Various
epidemiological
studies
shown
that
steady
consumption
fruits
vegetables
is
intensely
associated
reduced
risk
Since
ancient
period,
plants,
herbs,
other
natural
been
used
healing
agents.
Likewise,
most
medicinal
ingredients
accessible
today
are
originated
from
resources.
Regardless
achievements,
developing
bioactive
compounds
has
remained
challenging,
part
because
problem
large-scale
sequestration
mechanistic
understanding.
With
significant
progress
landscape
therapy
rising
use
cutting-edge
technologies,
we
may
come
crossroads
review
approaches
identify
potential
investigate
their
therapeutic
efficacy.
In
present
review,
summarize
recent
developments
products-based
research
its
application
generating
novel
systemic
strategies
focus
on
underlying
molecular
solid
Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: Nov. 10, 2022
With
cancer
incidence
rates
continuing
to
increase
and
occurrence
of
resistance
in
drug
treatment,
there
is
a
pressing
demand
find
safer
more
effective
anticancer
strategy
for
patients.
Natural
products,
have
the
advantage
low
toxicity
multiple
action
targets,
are
always
used
treatment
prevention
early
stage
supplement
late
stage.
Tumor
microenvironment
necessary
cells
survive
progression,
immune
activation
vital
means
tumor
eliminate
cells.
A
number
studies
found
that
various
natural
products
could
target
regulate
such
as
T
cells,
macrophages,
mast
well
inflammatory
cytokines
microenvironment.
tuning
via
mechanisms
activate
response
immeasurable
potential
immunotherapy.
In
this
review,
it
highlights
research
findings
related
regulating
responses
against
cancer,
especially
reveals
possibility
utilizing
remodel
overcome
resistance.
Cancers,
Journal Year:
2023,
Volume and Issue:
15(16), P. 4063 - 4063
Published: Aug. 11, 2023
Hepatocellular
carcinoma
(HCC)
is
one
of
the
most
aggressive
malignancies,
with
continuously
increasing
cases
and
fatalities.
Diagnosis
often
occurs
in
advanced
stages,
confining
patients
to
systemic
therapies
such
as
sorafenib.
Sorafenib
(SB),
a
multi-kinase
inhibitor,
has
not
yet
demonstrated
sufficient
efficacy
against
HCC.
There
strong
argument
favor
studying
its
use
combination
other
medications
optimize
therapeutic
results.
According
our
earlier
work,
crocin
(CR),
key
bioactive
component
saffron,
hinders
HCC
development
liver
cancer
stemness.
In
this
study,
we
investigated
CR
or
SB
cirrhotic
rat
model
evaluated
how
effectively
inhibited
tumor
growth
model.
Diethylnitrosamine
(DEN)
was
administered
intraperitoneally
rats
once
week
for
15
weeks,
leading
cirrhosis,
then
19
weeks
later,
multifocal
After
16
induction,
(200
mg/kg
daily)
(10
were
given
orally
three
either
separately
combination.
Consistently,
treatment
considerably
decreased
incidence
dyschromatic
nodules,
nodule
multiplicity,
dysplastic
nodules
when
compared
group
single
therapies.
Combined
therapy
also
caused
highest
degree
apoptosis,
along
proliferating
β-catenin
levels
tissues.
Additionally,
received
combined
CR,
it
showed
anti-inflammatory
characteristics
where
nuclear
factor
kappa
B
(NF-κB)
cyclooxygenase-2
(Cox-2)
additively
lowered.
As
result,
potentiates
suppressive
effects
on
provides
opportunity
strengthen
Naunyn-Schmiedeberg s Archives of Pharmacology,
Journal Year:
2023,
Volume and Issue:
396(11), P. 3087 - 3099
Published: May 9, 2023
Abstract
Cancer
cells
can
become
resistant
to
existing
treatments
over
time,
so
it
is
important
develop
new
that
target
different
pathways
stay
ahead
of
this
resistance.
Many
cancer
have
severe
side
effects
be
debilitating
and
even
life-threatening.
Developing
drugs
effectively
treat
while
minimizing
the
risks
these
essential
for
improving
quality
life
patients.
The
study
was
designed
explore
whether
combination
dicinnamoyl-L-tartaric
(CLT)
sorafenib
((SOR),
an
anti-cancer
drug))
could
used
hepatocellular
carcinoma
(HCC)
in
animal
model
assess
would
lead
changes
certain
biomarkers
associated
with
tumour.
In
study,
120
male
mice
were
divided
into
8
groups
15
each.
A
number
biochemical
parameters
measured,
including
liver
functions,
oxidative
stress
(malondialdehyde,
(MDA);
nitric
oxide
(NO)),
antioxidative
activity
(superoxide
dismutase
(SOD),
glutathione
peroxidase
(GPx)).
Furthermore,
hepatic
expressions
Bax
,
Beclin1
TNF
-
α
IL1β
BCl-2
genes
evaluated
by
qRT-PCR.
SOR
CLT
found
reduce
levels
enzymes,
such
as
AST,
ALT,
ALP,
GGT,
pathological
caused
DAB
PB.
upregulation
TNF-α
Bcl-2
suggests
able
initiate
inflammatory
response
combat
tumor,
downregulation
indicates
risk
apoptosis
liver.
therapy
led
increased
expression
cytokines,
resulting
enhanced
anti-tumor
effect.
